Search fresh public links, source activity, and ready-to-use post angles for Car-T.
Fresh curated links around CAR-T are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Chimeric antigen receptor (CAR) therapy is away you harness the specificity potential of antibodies and the killing potential of T cells. You make T cells to express bits of an ant...
The Delhi company designs and manufactures its own cell and gene therapies and is preparing a first clinical trial with Christian Medical College, Vellore.
With seven CAR T-cell therapies approved by the U.S. Food and Drug Administration, this innovative immunotherapy has revolutionized the treatment of blood cancers in recent years....
Researchers at Charité report promising results from the first CAR T-cell trial for treatment-refractory rheumatoid arthritis, with all six patients improving and three achieving s...
A new analysis of patients who took part in clinical trials for Kite Pharma’s CAR-T cell therapy Yescarta has revealed genetic signatures of toxicity risk, potentially providing a...
Featuring insights from Carl H. June, MD, FAACR, this post covers the ongoing challenges facing CAR T-cell therapy and some of the latest approaches that strive to overcome these h...
At 25, Michael Walters had already endured unsuccessful lymphoma treatments in New Zealand. A Melbourne hospital quoted up to US$600,000 for CAR-T therapy. He paid less than half t...
People have asked is CAR-T cell therapy the cure and the answer is I am not sure but can definately say that for some at least it is not as people can relapse after CAR-T therapy....
By modulating Notch and T cell receptor signaling, scientists have produced functional CD4+ T cells from iPSCs, potentially advancing scalable, off-the-shelf CAR T therapies. The p...
CAR-T’s commercial challenge is making thousands of patient-specific manufacturing runs behave like one reliable system. "In vivo" production techniques could be one solution.
A startup spawned from Seattle Children’s Hospital has raised a $116 million series A to advance cell therapies for devastating childhood brain tumors.
An allogeneic CAR T-cell therapy company is planning a pivotal Phase III randomized-control trial, hoping their products can reach more patients and help those who can’t access aut...
Advances in manufacturing, automation, and lentiviral vector technologies are reshaping the future of CAR T therapies. Ex vivo and in vivo approaches will evolve together, helping...
The emerging new class of in vivo CAR T therapeutics is seen by regulators as gene therapies with risks of off-target effects to patients. Manufacturers need to rise to the challen...
CAR T-cell therapy dramatically reduced disease activity in six people with severe rheumatoid arthritis that had resisted other treatments, with three achieving medication-free rem...
The immune system is full of T cells that could hunt down and destroy tumors, if they were primed. Now, a UC San Francisco team has invented a way to do this by combining immune ce...
Photo: www.lupusencyclopedia.com CAR-T cell therapy has been hailed as one of the most promising frontiers in autoimmune disease treatment, offering hope for long-term remission in...
The Gurugram-based company is developing allogeneic CAR-NK cell therapies made from healthy donor cells, backed by a $4.2 million seed round and a government grant covering both re...
A Precision-Built T-Cell Therapy Targets the B Cells Behind Myasthenia Gravis Myasthenia gravis is an autoimmune disorder in which the immune system attacks the body’s own machiner...
The HiBiT Target Cell Killing (TCK) platform, with off-the-shelf, mix-and-match components, measures four killing mechanisms for broad immunotherapy modality assessment. The post A...
We look at some of the top companies that are investigating CAR-T therapies in clinical trials for autoimmune diseases. The post Eight CAR-T companies tackling autoimmune disorder...
Scientists at St. Jude Children's Research Hospital have discovered that removing the gene for Regnase-1 from engineered immune cells makes them more effective at treating relapsed...
Colin Sample developed a rare bone marrow failure and then leukemia. But now, he is thriving with his family thanks to CAR T-cell therapy.
Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.